Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
2
May |
Technology Eases Migraine Pain In The Deep BrainCategory: Headache / Migraine | Leave a Comment |
Migraine pain sits at the upper end of the typical pain scale - an angry-red section often labeled “severe.” At this intensity, pain is debilitating. Yet many sufferers do not get relief from - or cannot tolerate - over-the-counter and commonly prescribed pain medications. Recently, a team of researchers that includes Dr…
|
2
May |
Technology Eases Migraine Pain In The Deep BrainCategory: Headache / Migraine | Leave a Comment |
Migraine pain sits at the upper end of the typical pain scale - an angry-red section often labeled “severe.” At this intensity, pain is debilitating. Yet many sufferers do not get relief from - or cannot tolerate - over-the-counter and commonly prescribed pain medications. Recently, a team of researchers that includes Dr…
|
8
Sep |
St. Jude Medical Announces European Regulatory Approval Of First Implanted Neurostimulation Device To Treat Chronic MigraineCategory: Headache / Migraine | Leave a Comment |
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced it has received the industry’s first and only regulatory approval for the use of an implanted neurostimulation device for patients with intractable chronic migraine…
|
27
Jun |
Autonomic Technologies Announces Positive Preliminary Findings For A Novel Device For The Treatment Of Severe HeadacheCategory: Headache / Migraine | Leave a Comment |
Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable system for severe headaches, today announced positive preliminary findings from a study evaluating the safety and efficacy of the company’s investigational neurostimulation system for the treatment of cluster headache. Jean Schoenen, M.D…
|
23
Jun |
Clinical Trial Data Demonstrating Benefit Of Neuromodulation For Chronic MigraineCategory: Headache / Migraine | Leave a Comment |
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, has announced study results on the safety and efficacy of peripheral nerve stimulation (PNS) of the occipital nerve for the management of pain and disability associated with chronic migraine, a debilitating condition that affects millions worldwide…
|
15
Jan |
SUMAVEL(TM) DosePro(TM) Available In The United States To Treat Acute Migraine And Cluster HeadachesCategory: Headache / Migraine | Leave a Comment |
Zogenix, Inc. (”Zogenix”), a privately held pharmaceutical company, and Astellas Pharma U.S., Inc. (”Astellas”) announced the U.S. commercial launch of SUMAVEL™ DosePro™ (sumatriptan injection) needle-free delivery system. In July 2009, the U.S…
|
7
Jan |
Innovative Medical Equipment Launches Sootheaway Device For Migraine ReliefCategory: Headache / Migraine | Leave a Comment |
Innovative Medical Equipment, LLC. (IME) has announced the full U.S. market release of SOOTHEAWAY - a new, thermo-electrically heated and cooled therapy device that helps relieve migraine, tension or stress headache pain in the forehead, temples, occipital and ocular / sinus regions. The compact SOOTHEAWAY device administers therapy at the optimal temperature for pain relief…
|
1
May |
Promise For Non-Drug Treatment Of Migraine From New Therapy Based On Magnetic StimulationCategory: Headache / Migraine | Leave a Comment |
IA new UCSF study examining the mechanism of a novel therapy that uses magnetic pulses to treat chronic migraine sufferers showed the treatment to be a promising alternative to medication. The therapy is called transcranial magnetic stimulation, or TMS. Study findings were presented April 29, 2009 during the annual American Academy of Neurology scientific meeting in Seattle.
|
12
Oct |
Pain In Chronic Headache Alleviated By Nerve Stimulation TherapyCategory: Headache / Migraine | Leave a Comment |
A novel therapy using a miniature nerve stimulator instead of medication for the treatment of profoundly disabling headache disorders improved the experience of pain by 80-95 percent, according to a new study from the University of California, San Francisco and the National Hospital for Neurology and Neurosurgery in London.